KLK3 and prostate carcinoma: The clinical utilization of current Food and Drud Administration (FDA) approved post‐DRE urine biomarkers for prostate cancer detection and monitoring provide an opportunity for parallel assessment of a PSA variant that may impact overall risk determination.